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Abstract
Background: Toll-like receptor (TLR)3 ligands serve as natural inducers of pro-inflammatory
cytokines capable of promoting Type-1 adaptive immunity, and TLR3 is abundantly expressed by
cells within the central nervous system (CNS). To improve the efficacy of vaccine strategies
directed against CNS tumors, we evaluated whether administration of a TLR3 ligand, polyinosinic-
polycytidylic (poly-IC) stabilized with poly-lysine and carboxymethylcellulose (poly-ICLC) would
enhance the anti-CNS tumor effectiveness of tumor peptide-based vaccinations.
Methods:  C57BL/6 mice bearing syngeneic CNS GL261 glioma or M05 melanoma received
subcutaneous (s.c.) vaccinations with synthetic peptides encoding CTL epitopes- mEphA2 (671–
679), hgp100 (25–33) and mTRP-2 (180–188) for GL261, or ovalbumin (OVA: 257–264) for M05.
The mice also received intramuscular (i.m.) injections with poly-ICLC.
Results: The combination of subcutaneous (s.c.) peptide-based vaccination and i.m. poly-ICLC
administration promoted systemic induction of antigen (Ag)-specific Type-1 CTLs expressing very
late activation antigen (VLA)-4, which confers efficient CNS-tumor homing of vaccine-induced
CTLs based on experiments with monoclonal antibody (mAb)-mediated blockade of VLA-4. In
addition, the combination treatment allowed expression of IFN-γ by CNS tumor-infiltrating CTLs,
and improved the survival of tumor bearing mice in the absence of detectable autoimmunity.
Conclusion: These data suggest that poly-ICLC, which has been previously evaluated in clinical
trials, can be effectively combined with tumor Ag-specific vaccine strategies, thereby providing a
greater index of therapeutic efficacy.
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Background
Our long-term goal is to develop safe and effective immu-
notherapeutic modalities for CNS tumors, such as glio-
mas. To this end, we have been directing our major focus
on factors that promote the efficacy of peripheral vaccina-
tions against CNS tumor-associated or specific Ags.
Indeed, our recent study using adoptive transfer of ex vivo
activated T-cells has demonstrated that a Type-1 pheno-
type for tumor-Ag specific CTLs is critical for efficient CNS
tumor-tropism and for the resulting anti-tumor therapeu-
tic efficacy, which can be further facilitated by genetic
delivery of IFN-α into CNS tumor sites [1].
While clinical development of adoptive transfer therapy
using Type-1 CTLs specific for glioma-associated antigens
(GAAs) and genetic delivery of IFN-α are feasible, efficient
vaccine-based approaches may be developed as more
logistically attractive alternatives, potentially by adminis-
tration of a "natural" inducers of IFN, such as a Toll-like
receptor (TLR)3 ligand, polyinosinic-polycytidylic acid
(poly-IC) [2,3], stabilized with poly-lysine and car-
boxymethylcellulose (poly-ICLC) [4] as adjuvants.
The TLRs play essential roles in the initiation of innate
and adaptive immunity. In mammals, the TLR family is
composed of at least 11–12 members; and each TLR acts
as a primary sensor of conserved microbial components,
driving the induction of specific biological responses
[5,6]. Among them, TLR3 is involved in the recognition of
viral components, such as viral double-stranded (ds)RNA,
and induces high levels of IFN-α/β [7-9]. Poly-IC serves as
a TLR3 ligand and promotes the generation of Type-1
polarizing dendritic cells (DC) [10] and the induction of
Type-1 Ag-specific immunity in vivo [11,12].
In the CNS and CNS tumors, recent studies have reported
that both microglia [13] and astrocytes express TLR3
[3,14]. Especially for human astrocytes, TLR3 appears to
be one of the most abundantly expressed TLRs [3], with
TLR3 ligation inducing the production of pro-inflamma-
tory cytokines such as IFN-α/β from astrocytes and micro-
glia [3,14,15]. These data suggest that TLR3-mediated
signaling may be key to expanding and directing systemic
immunity into the CNS [16]. Indeed, poly-ICLC has been
extensively evaluated as a single therapeutic agent in
patients with malignant glioma, demonstrating clinical
safety and feasibility [4]. Subsequent larger scale trials are
currently underway and the confirmation of safety for
poly-ICLC in these single-agent trials should support the
continued use of this agent in prospective combinational
vaccine trials.
As for integrin receptors involved in the adhesion of T-
cells to endothelia, very late antigen-4 (VLA-4, the het-
erodimer of α4 and β1 integrins) has been demonstrated
to confer T-cell homing to CNS inflammatory sites
[17,18]. Calzascia et al. have recently demonstrated that
up-regulation of VLA-4 on Ag-specific CTLs dictates effi-
cient CNS-tumor tropism [19]. Given that IFN-α up-regu-
lates VLA-4 on human T-cells [20], we hypothesized that
poly-ICLC might enhance VLA-4 expression on vaccine-
induced Ag-specific CTLs, thereby facilitating the CNS-
tumor homing of these CTLs. We now show that poly-
ICLC administration enhances the therapeutic efficacy of
the Ag-specific vaccines, in part, by promoting the induc-
tion of Type-1 Ag-specific VLA-4+ CTLs in the i.c. M05
melanoma and GL261 glioma models.
Methods
Animals
C57BL/6 (H-2b) and ovalbumin (OVA)-specific T-cell
receptor (TCR) transgenic OT-1 mice (C57BL/6-back-
ground) were purchased from Taconic (Germantown,
NY). Pmel-1 mice (The Jackson laboratory, Bar Harbor,
ME) are transgenic for a human(h)gp10025–33 – specific
TCR, which cross-reacts with mouse(m) gp10025–33. Ani-
mals were handled in the Animal Facility at the University
of Pittsburgh per an Institutional Animal Care and Use
Committee-approved protocol.
Cell lines
The mouse (H-2b) GL261 glioma cell line was kindly pro-
vided by Dr. Robert Prins (University of California, Los
Angeles, CA), with the OVA-transfected B16 (M05)
melanoma cell line kindly provided by Dr. Louis D. Falo,
Jr. (University of Pittsburgh, PA). These cell lines were
maintained in mouse complete medium [RPMI 1640 sup-
plemented with 10 % heat-inactivated fetal bovine serum,
100 units/mL penicillin, 100 µg/mL streptomycin, and 10
mmol/L L-glutamine (all reagents from Life Technologies,
Inc., Grand Island, NY)] in a humidified incubator in 5%
CO2 at 37°C.
Treatment of intracranial (i.c.) tumor-bearing mice with 
s.c. vaccination and i.m. poly-ICLC
Preparation of i.c. tumor-bearing mice was performed as
previously described [1,21,22]. Briefly, 5 × 103 M05 or 5 ×
104 GL261 cells in 2 µl PBS were stereotactically injected
through an entry site at the bregma 2 mm to the right of
the sagittal suture and 3 mm below the surface of the skull
of anesthetized mice using a stereotactic frame. The ani-
mals received s.c. vaccinations with corresponding pep-
tides emulsified in incomplete Freund Adjuvant (IFA)
(Difco Laboratories, Detroit, Michigan, MI) and i.m.
administrations with poly-ICLC (50 µg/injection; Onco-
vir Inc, Washington, DC) on indicated days. Animals were
monitored daily after treatment for the manifestation of
any pathologic signs. In some experiments, symptom-free
survival was monitored as the primary endpoint, and in
other experiments, treated mice were sacrificed on indi-Journal of Translational Medicine 2007, 5:10 http://www.translational-medicine.com/content/5/1/10
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cated days to evaluate immunological endpoints, such as
brain infiltrating lymphocytes (BILs).
Peptides and tetramers
All peptides, including H-2Kb-restricted OVA257–264 (SIIN-
FEKL), and mTRP2180–188  (SVYDFFVWL), H-2Db-
restricted hgp10025–33(KVPRNQDWL) and mEphA2671–
679  (FSHHNIIRL), I-Ab-binding HBV core128–140
(TPPAYRPPNAPIL), were synthesized in the University of
Pittsburgh Peptide Synthesis Facility, and were > 95%
pure as indicated by analytical high-performance liquid
chromatography and mass spectrometric analysis. Pep-
tides were dissolved in phosphate-buffered saline (PBS)/
10% dimethyl sulfoxide (DMSO) at a concentration of 2
mg/ml and stored at -20°C until use. Phycoerythrin (PE)-
conjugated- H-2Kb/TRP2180–188 tetramer was produced by
the National Institute of Allergy and Infectious Disease
(NIAID) tetramer facility at the Emory University Vaccine
Center (Atlanta, GA). PE-H-2Kb/OVA257–264 tetramer was
purchased from Beckman Coulter Inc. (Fullerton, CA).
Isolation of brain infiltrating lymphocytes (BILs)
BILs were isolated using the methods described previously
[1,23]. In brief, mice were sacrificed by CO2 asphyxia,
then perfused through the left cardiac ventricle with PBS.
Brains were mechanically minced and cells from each
brain were resuspended in 70% Percoll (Sigma, Saint
Louis, MO), overlayed with 37% and 30% Percoll, then
centrifuged for 20 min at 500 × g. Enriched BIL popula-
tions were recovered at the 70%-37% Percoll interface
[19,24]. For in vivo inhibition of α4-integrin, mice received
i.p. injections with anti-CD49d monoclonal antibodies
(mAbs) (150 µg/mouse for R1-2 and 9C10; BD PharMin-
gen, San Diego, CA) or 300 µg/mouse isotype rat IgG2bK,
(clone A95-1; BD PharMingen, San Diego, CA) at the indi-
cated time points.
Antibodies and flow cytometry
TriColor (TC)-anti-CD3, fluorescein isothiocyanate
(FITC)-anti-CD8α, PE-anti-CD8α, TC-anti-CD8, PE-anti-
H-2Kb, FITC-anti-CD49d (α4-integrin), FITC-anti-
TCRvβ13, purified anti-CD49d (clones R1-2 and 9C10)
mAbs were purchased from BD PharMingen (San Diego,
CA). PE-anti-TLR3 was purchased from eBioscience. IFN-
β-neutralizing mAb (MIB-5E9.1) and the corresponding,
functional grade, purified Armenian hamster IgG
(eBio299Arm) were obtained from BioLegend and eBio-
science, respectively. Single-cell suspensions of spleno-
cytes (SPCs), lymph node (LN) cells and BILs were stained
with 10 µg/ml PE-labeled MHC-peptide-specific tetramers
in PBS containing 1% BSA for 15 min at room tempera-
ture, then washed once and stained with TC-anti-CD3 or
FITC-anti-CD8 mAbs. For intracellular IFN-γ staining,
cells were surface-stained with PE-anti-CD8 mAb, washed,
fixed, and then permeabilized with Cytofix/Cytoperm
buffer (BD PharMingen) before staining with anti-IFN-γ
mAb (BD PharMingen). Flow-cytometric analyses were
performed using Coulter EPICS cytometer for lym-
phocyte-gated cell populations (Beckman Coulter, Fuller-
ton, CA).
In vivo CTL assay
C57BL/6 mice were immunized s.c. with the OVA (100
µg) and the helper HBV Core128–140 (150 µg) peptides
emulsified in IFA and i.m. poly-ICLC (50 µg/ml) on days
0 and 7. On day 14, erythrocyte-depleted SPC and lymph
node cells from naïve C57BL/6 mice were either: 1)
pulsed with 10-6 M OVA-peptide, incubated at 37°C for 1
hour, and labeled with a high concentration of Carboxy-
fluorescein diacetate, succinimidyl ester (CFDA SE; CFSE)
(2.5 µM) (CFSEhigh cells); or 2) pulsed with no peptide
and labeled with a low concentration of CFSE (0.25 µM)
(CFSElow cells). Then, equal numbers of cells from each
populationwere mixed and i.v. infused into immunized
mice (1 × 107 cells in 200 µl PBS/mouse). At 4 hrs after i.v.
infusion, SPC were evaluated for the ratio of CFSElow to
CFSEhigh cells by flow cytometry. To calculate specific lysis,
the following formula was used: ratio = (percentage
CFSElow/percentage CFSEhigh). Percentage specific lysis =
[1 – (ratio unprimed/ratio primed) × 100] [25].
In vitro CTL assay
C57BL/6 mice were immunized s.c. with synthetic,
GL261-derived CTL epitopes (50 µg TRP-2180–188  and
hGP10025–33, 100 µg mEphA2671–679) and the helper pep-
tide (150 µg HBV Core128–140) emulsified in IFA (GAA-
vaccine) in combination with i.m. poly-ICLC on days 0
and 7. SPCs were harvested on day 14, and in vitro re-stim-
ulated for 5 days with IL-2 (20 IU/ml) and each of (5 µg/
ml) three GAA peptides before SPCs were tested for their
lytic activity against GL261 glioma cells and control, GAA-
negative EL-4 cells in a 4-hr standard 51Cr-release assay as
previously described [22].
Cytokine release assay
Single cell-suspended BILs, SPCs and LN cells were restim-
ulated with OVA257–264 peptide (5 µg/ml) in the presence
of rhIL-2 (20 U/ml) for indicated time. Culture superna-
tants were assessed for mIFN-γ using a specific ELISA kit
(BD PharMingen, San Diego). IFN-inducible protein (IP)-
10 production levels from tumor cells were determined by
mIP-10 ELISA kit (R&D, Minneapolis, MN).
Histological analyses of i.c. tumors
Perfusion-fixed brains were obtained from mice treated
with GAA-vaccine and poly-ICLC on day 90 after the
tumor inoculation. The brains were then embedded in
optimal cutting temperature compound (4583; Sakura
Finetek), frozen at -80°C, and thin coronal sections [20
µm for Luxol Fast Blue (LFB) and 5 µm for HematoxylinJournal of Translational Medicine 2007, 5:10 http://www.translational-medicine.com/content/5/1/10
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& Eosin (H&E)] were made using a cryostat. Sections were
stained with H&E to evaluate the overall infiltration of
mononuclear immune cells, or with LFB to evaluate the
demyelination.
Statistical analysis
Survival data were compared using Log rank test. Compar-
ative T-cell responses were analyzed by one way analysis
of variance for comparing means of three or more varia-
bles, ANOVA).
Results
EphA2 is an antigen associated with GL261 glioma, but not 
normal brain
GL261 glioma cells (H-2b) express well-characterized CTL
epitopes, such as the H-2Db-restricted mgp10025–33 and
the H-2Kb-restricted TRP-2180–188 peptides [26]. In addi-
tion, we recently identified a novel T cell epitope H-2Db-
restricted mEphA2671–679, derived from the receptor tyro-
sine kinase mEphA2, which is overexpressed in human
[27] and murine gliomas, including GL261 [28]. We
hereby define these three antigens (mgp100, TRP-2 and
EphA2) as the glioma-associated antigens (GAAs) in the
GL261 glioma cells. As demonstrated in Fig. 1, immuno-
staining revealed a high-level expression of EphA2 in the
GL261 tumor; whereas the normal brain did not demon-
strate significant staining. These results confirm the West-
ern Blot analyses reported in our previously published
study [28]. In the case of the M05 melanoma model sys-
tem, the OVA257–264  peptide represents an additional
"tumor" epitope [1].
I.m. poly-ICLC administration enhances specific CTL 
responses against OVA and GAA-derived CTL epitopes
We sought to determine whether poly-ICLC administra-
tion could enhance the induction of specific CTL response
to peptide epitopes employed in vaccines. In vivo CTL
assays against OVA257–264-peptide demonstrated that con-
current i.m. poly-ICLC and OVA peptide-based vaccine
administration yielded remarkably enhanced induction
of specific CTL responses in both SPCs and draining LN
cell populations (Fig. 2A). Furthermore, i.m. poly-ICLC
administration augmented anti-GL261 CTL responses
induced by vaccinations with 3 endogenous GAAs,
mEphA2671–679, hgp10025–33and TRP-2180–188 in addition
to the HBVcore128–140 T-helper epitope (GAA-vaccines)
(Fig. 2Ba). EL-4 thymoma cells that do not express these
GAAs were used as negative control target cells, and were
poorly recognized (< 10% lysis) in all groups (Fig. 2Bb),
supporting the specificity of the vaccine-induced CTL
responses. Poly-ICLC administration also enhanced the
SPC-production of IFN-γ following vaccinations with
mEphA2671–679 (Fig. 2C).
Poly-ICLC facilitates the infiltration of Ag-specific T cells 
into the CNS tumor site
To determine whether poly-ICLC administration
enhanced the infiltration of brain tumors by vaccine-
induced OVA257–264- specific CTLs, C57BL/6 mice bearing
intracranial (i.c.) M05 tumor received vaccinations using
OVA peptide with or without poly-ICLC for two cycles
prior to isolation of BILs. The percentage (Fig. 3A) and the
absolute numbers of CD3+/OVA tetramer+ BILs per mouse
(Fig. 3B) were then analyzed by flow cytometry. As dis-
played in Figs. 3Aa and 3Ba, there were relatively few
OVA-tetramer/CD3-double positive BILs in mice that had
received mock-vaccination or poly-ICLC alone. Even
though the percentage of OVA-tetramer/CD3-double pos-
itive cells appeared to be slightly elevated as a result of
poly-ICLC treatment alone (Fig. 3Aa), the actual number
of these cells was still low, due to the low total number of
BIL obtained from this group (Fig. 3Ba). Although OVA-
vaccines appeared to have increased the total number of
OVA-specific T-cells moderately, due to the increase of
total CD3+ lymphocytes in this group compared to groups
treated with poly-ICLC alone or mock-treated mice (Fig.
3Ba), the numbers of OVA-tetramer/CD3-double positive
cells remained less than 1000/mouse in these three
groups in 2 independent experiments. In contrast, the
addition of poly-ICLC to the OVA-vaccine regimen
remarkably increased tumor-infiltration by OVA-specific
responder T cells (3,900/mouse).
To improve the sensitivity and reliability of flow-cytome-
try based enumeration of BILs, in parallel experiments, i.c.
M05 bearing mice received i.v. transfer of naïve OT-1
mice-derived SPCs and LN cells prior to the first immuni-
zation. As demonstrated in Figs. 3Ab and 3Bb, the combi-
nation therapy with OVA-vaccines and i.m. poly-ICLC
administrations resulted in a remarkable increase in the
percentage (Fig. 3Ab), and in the absolute numbers (2.06
× 105/mouse) (Fig. 3Bb) of OVA-specific CD3+ BILs per
mouse compared to other groups including mice receiv-
ing OVA-vaccines alone (2.05 × 104/mouse).
To evaluate whether the increased numbers of OVA-reac-
tive T-cells were also evident systemically, we also har-
vested lymphocytes from the spleen, draining inguinal
LNs and cervical LNs, and evaluated these populations for
their frequencies of OVA-reactive CD8+ T cells. The per-
centage of OVA257–264-reactive CD3+ T cells among total
lymphocyte gated populations ranged from 0.54 – 1.05%
and 0.34–0.65% in mice treated with both OVA-vaccines
plus poly-ICLC, vs. mice treated with OVA-vaccines alone,
respectively (data not shown). Hence, poly-ICLC admin-
istration in combination with OVA-vaccination preferen-
tially promoted the infiltration of vaccine-induced OVA-
specific T-cells into brain tumor sites.Journal of Translational Medicine 2007, 5:10 http://www.translational-medicine.com/content/5/1/10
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To assess the functional status of BILs, freshly-isolated
BILs were evaluated for expression of IFN-γ following a
brief (6 hrs) in vitro re-stimulation with the OVA257–264-
peptide and low-dose rhIL-2 (Fig. 3Ca). BILs obtained
from mice receiving both OVA-vaccines and poly-ICLC
produced high levels IFN-γ, whereas IFN-γ levels were
undetectable in all other groups. SPCs and LN cells
obtained from mice receiving the combination therapy
produced higher levels of IFN-γ than those obtained from
other groups following 96 hr in vitro stimulation (Fig.
3Cb–d) (P < 0.001). These results suggest that poly-ICLC
delivery enhances Type-1 (i.e. IFN-γ expressing) function
of vaccine-stimulated T cells, especially within the i.c.
tumor-microenvironment.
Poly-ICLC treatment up-regulates VLA-4 expression on 
OVA-specific T cells that dictates their CNS-tumor homing 
capacity
Efficient CNS-tumor homing of Ag-specific T-cells acti-
vated by Ag-specific vaccines and poly-ICLC administra-
tion led us to determine whether poly-ICLC
administration induces qualitative changes in the pheno-
type of vaccine-activated OVA-reactive T cells particularly
in the context of homing receptors involved in brain
High-level expression of EphA2 is restricted to GL261 glioma in the mouse brain Figure 1
High-level expression of EphA2 is restricted to GL261 glioma in the mouse brain. Paraffin embedded tissue sections 
prepared from the brains of C57BL/6 mice bearing day 14 GL261 glioma in the right frontal lobe were stained with anti-EphA2 
monoclonal antibody (C-20 Ab; Santa Cruz Biotechnology, Inc). After washing, sections were incubated with biotinylated goat 
anti-rabbit IgG (Vector Laboratories), followed by avidin-biotin-complex peroxidase (Vectastain ABC kits; Vector Laborato-
ries). Reaction products were developed using a Nova Red substrate kit (Vector Laboratories) giving rise to red-brown depos-
its. The sections were also counter-stained with hematoxylin (blue). The letter "T" in the figure indicates tumor tissue, with the 
letter "N" in the figure indicating normal brain tissue. Original magnification; × 20.
N
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tumor-tropism. Based on a recent study by Calzascia et al.
demonstrating that up-regulation of VLA-4 expression on
Ag-specific CTLs confers efficient CNS-tumor tropism
[19], we evaluated expression of CD49d (Integrin α4
chain), a subunit for the VLA-4, on BILs (Fig. 4A) and
SPCs (Fig. 4B) obtained from mice receiving OVA-vac-
cines and/or i.m. poly-ICLC administrations. As depicted
in Fig. 4A, in vivo administration of poly-ICLC remarkably
increased the number of α4-integrin (CD49d)+  OVA-
tetramer binding CD8+ cells in BILs. Although the percent-
age was lower compared to BILs, the combination regi-
men also increased the numbers of α4-integrin (CD49d)+
OVA-tetramer binding cells in SPCs (Fig. 4B). These cells
also expressed β1-integrin (CD29), but did not express
detectable α4β7 integrin heterodimers (data not shown),
indicating that α4-integrin (CD49d) is solely expressed in
VLA-4 complexes.
We next performed parallel experiments using i.c. GL261-
bearing mice treated by adoptively transfer of naïve Pmel-
1 derived CD8+ cells followed by vaccination with gp100
peptides and poly-ICLC administration. We observed
results similar to the M05 model, with increased i.c. gli-
oma-infiltration by α4-integrin/TCR-Vβ13 double-posi-
tive cells as a result of this treatment regimen (Fig. 4C).
VLA-4 allows activated T-cells to adhere to vascular cell-
adhesion molecule (VCAM)-1+ endothelial cells [17,18].
Therefore, these data suggest the possibility that VLA-4
may play a significant role in the CNS-tumor homing of
Poly-ICLC administration enhances vaccine-induced specific CTL generation in vivo Figure 2
Poly-ICLC administration enhances vaccine-induced specific CTL generation in vivo. (A), C57BL/6 mice received 
OVA-vaccines with or without i.m. poly-ICLC on days 0 and 7 (n = 3/group). OVA-specific CD8+ T cell activities in SPC (a) 
and draining inguinal LN cells (b) were evaluated by in vivo CTL assays on day 14. *P < 0.01 for the combination group com-
pared with poly-ICLC alone or control group; and P < 0.05 for the combination group compared with vaccine alone group. #P 
> 0.05 for the group receiving vaccine alone compared with poly-ICLC alone or control group. (B), C57BL/6 mice received 
GAA-vaccines with or without i.m. poly-ICLC on days 0 and 7. SPCs were harvested on day 14. Following a 5-day in vitro stim-
ulation with 20 IU/ml IL-2 and three GAA peptides, SPCs were tested for their lytic activity against GL261 glioma cells (a) or 
EL4 cells (b) in a 4-hr standard 51Cr-release assay. (C), C57BL/6 mice received EphA2-vaccines with or without i.m. poly-ICLC 
on days 0 and 7. On day 14, SPC were harvested, in vitro stimulated with low-dose (20 IU/ml) hIL-2 and mEphA2671–679 for 5 
days prior to performance of mouse IFN-γ specific ELISA using culture-supernatants. *P < 0.001 compared to vaccine alone, 
poly-ICLC alone and the control groups. For (A-C), n = 3/group, and data represent results from one of 3 independent exper-
iments performed with similar results obtained. Error bars represent standard deviation (SD).
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CTLs induced by vaccine plus poly-ICLC co-treatment. To
address this hypothesis, we evaluated the effects of spe-
cific mAb-mediated blockade of the VLA-4/VCAM-1 inter-
action (Fig. 4D). Before these in vivo experiments, we
confirmed that each of two anti-α4-integrin mAbs (Clones
R1-2 and 9C10), and especially the combination of these
two mAbs, effectively blocked the binding of activated T-
cells to plastic plates coated with VCAM-1 (Sasaki et al.
submitted). C57BL/6 mice bearing day 10 i.c. M05 tumors
received i.p. injections of anti-α4-integrin mAbs (R1-2,
and 9C10), or control isotype mAb (rat IgG2bK, clone,
A95-1) 2 hrs prior to i.v. adoptive transfer of 5 × 106 naïve
OT-1 mouse-derived T-cells, which was immediately fol-
lowed by OVA-vaccination and poly-ICLC administra-
tion. On day 13, i.p. mAb injections and vaccinations
were repeated. BILs were harvested on day 16, and evalu-
ated by flow cytometry. As depicted in Fig. 4D, the func-
tional blockade of α4-integrin by specific mAbs
Poly-ICLC administration promotes the infiltration of Type-1 Ag-specific T cells into CNS rumor sites Figure 3
Poly-ICLC administration promotes the infiltration of Type-1 Ag-specific T cells into CNS rumor sites. (A-C), 
mice bearing day 10 M05 tumors were immunized with either: OVA257–264vaccines plus poly-ICLC, OVA257–264 vaccines only, 
mock vaccines plus poly-ICLC, or control mock vaccines on days 10 and 15. In the experiments depicted in (A-b, B-b, C), mice 
also received i.v. injections of 5 × 106 OT-I mice-derived naïve SPCs and LN cells on day 10 prior to the first immunization. On 
day 16, the mice were sacrificed, and BILs from tumor-bearing hemisphere were analyzed for the presence of OVA257–264-spe-
cific T-cells using TC-labeled anti-mouse CD3 mAb and PE-labeled OVA257–264-specific tetramer. N = 5 mice/group. BILs from 
the same group were pooled and compared between groups. (A), numbers represent the percentage of CD3+/OVA tetramer+ 
cells in lymphocyte-gated BILs. (B), total numbers of CD3+/OVA tetramer+ BILs per mouse with (b) or without (a) adoptive 
transfer of naïve OT-1 mouse-derived SPCs and LN cells. (C), expression of IFN-γ by isolated BILs (a), SPCs (b), ipsilateral 
inguinal (c), and cervical (d) LN cells. Aliquots of 1.0 × 106/ml isolated lymphocytes were cultured with 5 µg/ml OVA257–264 and 
20 IU/ml rhIL-2 for 6 h (BILs) or 5 days (for SPCs and LN cells), and IFN-γ in the supernatant was measured by specific ELISA. 
For BILs (a), *P < 0.05 compared to all other groups. For SPCs (b), *P < 0.001 compared to all other groups. For iLNs (c) and 
cLNs (d), *P < 0.001 for the combination group compared to all other groups, #P < 0.01, for the vaccine alone group com-
pared to the control or the poly-ICLC alone group. Columns, mean of three wells in 96 well plate; Error bars, SD. Representa-
tive of 2 and 4 independent experiments with similar results, for (a) and (b), respectively.
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diminished the CNS-tumor homing of OVA-specific T-
cells. Treatment with mAbs did not affect the peripheral
expansion of OVA-reactive T-cells, as the numbers of
OVA-tetramer reactive T-cells in lymphoid organs were
not significantly altered by mAb treatments (Fig. 4E).
These data suggest that the mAb-mediated blockade of α4-
integrin inhibits the tumor-homing of these effector cells,
but not their induction or expansion. Even though effi-
cient tumor-homing by Ag-specific CD8+ T cells most
likely results from the orchestrated cooperation of multi-
ple receptor-ligand combinations [29], these results indi-
cate that poly-ICLC induced VLA-4 expression on vaccine-
induced CTL dominantly influences their capacity to infil-
trate into CNS tumors.
Combination vaccine + poly-ICLC therapy is an effective 
treatment for mice bearing CNS glioma and induces long 
term anti-tumor protection
To evaluate whether the enhanced, systemic and local Ag-
specific T-cell responses stimulated by the combination
Poly-ICLC enhances the T-cell expression of α4-integrin (CD49d), which confers efficient CNS-tumor homing of Ag-specific T- cells Figure 4
Poly-ICLC enhances the T-cell expression of α4-integrin (CD49d), which confers efficient CNS-tumor homing 
of Ag-specific T-cells. (A and B), C57BL/6 mice bearing day 10 i.c. M05 tumors received 5 × 10 6 naive OT-1 mouse-derived 
T-cells, then OVA-vaccines and/or poly-ICLC administrations on days 10 and 15. BILs (A) and SPCs (B) were harvested on day 
16, and evaluated for the α4-integrin expression on CD8+, OVA-tetramer+ cells by flow cytometry. (A), numbers represent the 
percentage of α4-integrin+/CD8+ (upper panel), α4-integrin+/OVA+ cells (lower panel) in lymphocyte-gated BIL populations. (B), 
numbers represent the percentage of α4-integrin+/OVA+ cells in lymphocyte-gated SPC populations. (C), C57BL/6 mice bearing 
day 15 i.c. GL261 tumors received 5 × 10 6 naive Pmel-1 mouse-derived T cells, then hgp100-vaccines and/or poly-ICLC admin-
istrations on days 15 and 20. BILs were harvested on day 21, and evaluated for the α4-integrin expression on CD8+/TCRvβ13+ 
cells by flow cytometry. Numbers represent the percentage of α4-integrin+/TCRvβ13+ T-cells in lymphocyte-gated populations. 
(D and E), mAb-mediated blockade of α4-integrin inhibited the CNS-tumor infiltration of OVA-specific T-cells, while not 
depleting Ag-reactive T-cells systemically. C57BL/6 mice bearing day 10 i.c. M05 tumors received i.p. injections of anti-α 4-
integrin mAbs (R1-2, 150 µg/mouse and 9C10, 150 µg/mouse), or control isotype mAb (rat IgG2bK, clone, A95-1, 300 µg/
mouse) at 2 hrs before i.v. adoptive transfer of 5 × 106 naïve OT-1 mouse-derived T-cells and subsequent OVA-vaccination and 
poly-ICLC administration. On day 13, the mice received the 2nd OVA-vaccination and poly-ICLC administration at 2 hrs follow-
ing the 2nd i.p. mAb injections. BILs, SPC and lymphocytes from draining inguinal (i)LNs were harvested on day 16. Numbers of 
CD3+/OVA tetramer+ BILs per mouse (D), and the presence of CD8+, OVA-tetramer reactive T cells in iLN and SPC are 
depicted (E). Data are representative of 3 independent experiments with similar results.
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therapy would translate into a more clinically-relevant
model, C57BL/6 mice were pre-immunized with GAA-
vaccines on days -14 and -7, with or without poly-ICLC
administration, before they received i.c. injection of 5 ×
104 GL261 cells in the right hemisphere on day 0. As
depicted in Fig. 5A, all mice receiving mock treatments
died by day 47. Treatment with poly-ICLC alone had no
therapeutic effect when compared to the mock vaccine
group (P > 0.05). Although GAA-vaccination alone
resulted in long-term (> 90 days) survival in 3 of 10 mice,
this level of protection did not reach statistical signifi-
cance when compared to the control, mock treatment
group (p = 0.0521). In contrast, addition of poly-ICLC to
the GAA-vaccine protocol improved survival, with 9 of 15
animals still alive on day 90, a statistically significant ben-
efit when compared with the control (P = 0.003) group.
To further determine whether i.c. tumor-bearing mice
immunized with GAA-vaccines and poly-ICLC exhibit
long-term anti-tumor memory immune response, survi-
vors in experiments in Fig. 5A were re-challenged with 5 ×
104 GL261 cells in the contralateral hemisphere of the
brain on day 90 after the initial tumor inoculation. As a
control group, non-immunized age-matched mice also
received the same i.c. GL261 cell-inoculations. On day 7
after tumor re-challenge, mice were sacrificed, and BILs
were harvested. As shown in Fig. 5B, flow-cytometric anal-
yses of BILs revealed an elevated percentage of H-2Kb/
TRP-2180–188 tetramer reactive CD8+ T cells in the vacci-
nated, long-term survivors when compared to BILs
obtained from control non-immunized GL261-bearing
mice. Furthermore, mice received the combinational regi-
men exhibited approximately 3-fold higher numbers of
CD8+ BILs when compared to mice treated with GAA-vac-
cines alone (Fig. 5C). These results strongly suggest that
the GAA-vaccines in combination with poly-ICLC, can
induce effective, long-term memory responses that are
protective against i.c.GL261 progression.
Luxol Fast Blue (LFB) and Hematoxylin and Eosin (H&E) 
staining suggest the lack of autoimmune encephalitis in 
mice treated with GAA-vaccines and poly-ICLC
To determine whether the combination therapy with
GAA-vaccines and poly-ICLC administration induces
demyelination and/or autoimmune encephalitis, we eval-
uated brain sections obtained from treated mice by LFB
staining and H&E staining using standard protocols [30].
Fig. 6 depicts representative stained sections derived from
mice treated with the combinational regimen. Highly-
myelinated structures, such as corpus callosum and inter-
nal capsule, were densely stained with LFB. There was no
evidence of demyelination or abnormal immune cell
infiltration throughout the brain. We also examined con-
trol mice treated with GAA-vaccines alone or with mock-
vaccines, and found no evidence of autoimmunity in
these animals (data not shown).
Discussion
Our current study is novel and significant for several rea-
sons. We report that: 1) poly-ICLC can serve as a safe and
effective adjuvant to improve the efficacy of Ag-specific
peripheral vaccinations in mouse CNS tumor models,
including the GL261 glioma; 2) VLA-4 expression on CTLs
plays a significant role in the efficient CNS tumor infiltra-
tion of Ag-specific CTLs induced by the vaccinations and
poly-ICLC treatment; 3) efficient CNS tumor homing of
Ag-specific T-cells was also associated with Ag-specific
IFN-γ production of BILs, suggesting the improved Type-1
function of tumor infiltrating CD8+ T effector cells as a
result of poly-ICLC co-administration. Our data with both
GL261 glioma and M05 melanoma models provide us
with insights that may be applicable to immunotherapy
for both primary and metastatic CNS tumors.
With regard to the underlying mechanisms supporting the
enhanced induction of Ag-specific CTLs by TLR3 stimula-
tion in our systems, recent studies using poly-IC in murine
tumor models have demonstrated that poly-IC increases
the transcription of the anti-apoptotic molecules Bcl-3
and Bcl-xL in T cells, thereby inhibiting their apoptosis
[12], and that poly-IC-induced activation of natural killer
(NK) cells, which is dependent on host-derived IFN-γ, IL-
12 and IL-15, is at least partially responsible for the adju-
vant effects of poly-IC [11]. In this referenced study, it was
also noted that the timing of poly-IC administration was
critical. Enhanced Ag-specific CD8+ T cell responses were
observed only when poly-IC was administered within 4
hrs following peptide vaccination. Although these studies
provide valuable insights regarding the mechanisms
underlying the adjuvant effects of poly-ICLC, we have
observed prolonged elevation of serum IFN-α response
(at least for 48 hrs) (Fig. 7) than reported data using poly-
IC [11], most likely due to the improved chemical stability
of poly-ICLC when compared to poly-IC. Induction of
systemic IFN-α is likely to play a critical role in our
observed data because of its ability to mature DCs
[10,31,32], promote cross-priming [33] and sustain the
survival of activated T-cells [34,35]. Indeed, TLR3-medi-
ated stimulation has been reported to enhance CD8+ T-
cell responses against OVA-protein in an IFN-α/β signal-
ing-dependent manner [36]. We are currently evaluating
the role of the host IFN-α/β responsiveness in the promo-
tion of GAA-specific CTLs using IFN-α/β receptor-/- mice
as recipients in our i.c. tumor models.
Our data demonstrating that VLA-4 expression on vac-
cine-induced CTLs plays a major role in their efficient
CNS-tumor homing confirm a recent study using an alter-
nate CNS tumor model [19]. Our data also suggest thatJournal of Translational Medicine 2007, 5:10 http://www.translational-medicine.com/content/5/1/10
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GAA-vaccines in combination with i.m. poly-ICLC administrations induce long-term anti-GL261 protective immunity Figure 5
GAA-vaccines in combination with i.m. poly-ICLC administrations induce long-term anti-GL261 protective 
immunity. (A), C57BL/6 mice received s.c. GAA-vaccines with or without i.m. poly-ICLC on days -14 and -7. On day 0, mice 
received i.c. inoculations of 1 × 105 GL261 cells, with survival subsequently monitored. **P = 0.003 for the mice receiving com-
bination treatments compared with the control group. *P = 0.0521 for the mice receiving GAA-vaccines alone compared with 
the control group (Log rank test). (B and C), mice that survived for 90 days following GAA-vaccines and i.m. poly-ICLC or 
GAA-vaccine alone in (A) were re-challenged with 5 × 104 GL261 in the contralateral hemisphere of the brain (n = 3/group). 
As controls, naïve mice received the same number of GL261 cells. BILs were harvested from the tumor-bearing hemisphere at 
7 days after tumor re-challenge, and stained with TC-anti-CD8 and PE-H-2Kb/TRP2180–188-specific tetramer. (B), numbers rep-
resent the percentage of CD8+/TRP-2 tetramer+ cells in lymphocyte-gated BILs in each group. (C), numbers of viable CD8+ 
BILs per mouse.
A
0 10 20 30 40 50 60 70 80 90
0
25
50
75
100
Control
poly-ICLC
Vaccine
Vaccine+Poly-ICLC
Days After Tumor Injection
P
e
r
c
e
n
t
S
u
r
v
i
v
a
l
(
%
)
**
*
**
*
A
0 10 20 30 40 50 60 70 80 90
0
25
50
75
100
Control
poly-ICLC
Vaccine
Vaccine+Poly-ICLC
Days After Tumor Injection
P
e
r
c
e
n
t
S
u
r
v
i
v
a
l
(
%
)
**
*
**
*
**
*
**
*
TRP2-Tetramer
C
D
8
Vaccine
Control
0.43
1.80
3.30
Vaccine+
Poly-ICLC
BC
Vaccine
0
1
2
3
4
5
6
7
8
Vaccine+
poly-ICLC
C
D
8
+
B
I
L
N
u
m
b
e
r
/
M
o
u
s
e
(
x
1
0
e
3
)
D
TRP2-Tetramer
C
D
8
Vaccine
Control
0.43
1.80
3.30
Vaccine+
Poly-ICLC
TRP2-Tetramer
C
D
8
Vaccine
Control
0.43
1.80
3.30
Vaccine+
Poly-ICLC
BC
Vaccine
0
1
2
3
4
5
6
7
8
Vaccine+
poly-ICLC
C
D
8
+Journal of Translational Medicine 2007, 5:10 http://www.translational-medicine.com/content/5/1/10
Page 11 of 15
(page number not for citation purposes)
poly-ICLC administration promotes not only the systemic
induction of Ag-specific CTLs, but alters their profile of
surface receptors expressed allowing for the efficient CNS-
tumor homing. The precise mechanism(s) as to how poly-
ICLC promotes VLA-4 expression on T-cells requires fur-
ther investigation. Both Type-1 helper T-cells [i.e. Th1;
[37]] and Type-1 CD8+ T cells [i.e. Tc1; [38]] express
higher levels of VLA-4 when compared to their Type-2
counterparts. With regard to direct cytokine signals that
promote VLA-4 expression, IFN-α appears to up-regulate
VLA-4 on human T cells [20]. Therefore, it is likely that
poly-ICLC induces VLA-4 expression on T-cells by sup-
porting a Type-1 cytokine milieu that includes IFN-α.
Experiments to evaluate this hypothesis using IFN-α/β
receptor-/- mice appear warranted.
Our studies evaluating IFN-γ production from freshly-iso-
lated BIL and in vitro stimulated LN cells suggested that
H&E and LFB staining of brain sections reveal the absence of pathologic autoimmunity Figure 6
H&E and LFB staining of brain sections reveal the absence of pathologic autoimmunity. Perfusion-fixed brains 
were obtained from GL261-bearing mice treated with GAA-vaccine and poly-ICLC on day 90 after the tumor-inoculation. Fro-
zen sections were stained with LFB (B and D). Cryostat sections were also stained with H&E to evaluate the overall infiltration 
of mononuclear immune cells (A and C). Images were taken from the basal ganglia. The thick bundle strongly stained with LFB 
indicates internal capsule. All images were obtained from the corresponding visual fields. The original magnifications are × 10 
(for A and B), and × 20 (for C and D). There was no evidence of demyelination, hemorrhage, or pathological immune cell infil-
tration throughout the brain.
A
C D
BJournal of Translational Medicine 2007, 5:10 http://www.translational-medicine.com/content/5/1/10
Page 12 of 15
(page number not for citation purposes)
poly-ICLC administration systemically promotes Ag-spe-
cific, Type-1 T cell responses. This is likely to be mediated
through the activation of NK and antigen-presenting cells
(APCs) by poly-ICLC, since these cells express TLR3 [39-
41], and these cells co-stimulate each other in the pres-
ence of poly-IC in promoting both the Type-1 polarizing
functions of DC [42] and the enhanced cytotoxic ability of
NK cells [43]. As IFN-γ was produced in response to MHC
class I-restricted, OVA peptide stimulation [44,45], these
results strongly suggest that poly-ICLC promotes specific
Type-1 CTL (Tc1) responses that favor efficient tropism
into CNS tumors, as well as therapeutic efficacy [1].
Our results showing high level IFN-γ production from
BILs derived from mice treated with vaccination + poly-
ICLC administration suggest the possibility that i.m.
delivery of poly-ICLC directly stimulates the functions of
APCs and other immune cells infiltrating the CNS tumors,
such as microglia, thereby providing the secondary stimu-
lation of vaccine-induced Ag-specific CTLs within the
CNS-tumor environment. Experiments evaluating this
hypothesis are currently underway.
In vitro stimulation of cultured GL261 cells with poly-
ICLC induced secretion of IFN-β and IP-10, as well as
upregulation of the TLR3 and MHC class I (H-2Kb) mole-
cules (Fig. 8). Interestingly, the upregulation of H-2Kb,
but not IP-10, was at least partially dependent upon poly-
ICLC-induced IFN-β signaling as demonstrated by block-
ade of Type-I IFN (IFN-β) signaling using IFN-β specific
mAb (Fig. 8). As upregulated MHC class I expression
directly mediates recognition by Ag-specific T-cells in
inflammatory conditions [46,47], these results suggest
that poly-ICLC treatment may directly sensitize GL261 gli-
oma cells to the CTL-mediated immuno-surveillance via
induction of Type-I IFN and the resultant upregulation of
MHC class I and IP-10 production. In our previous study
[1], IFN-induced chemokine IP-10 played a critical role in
the efficient recruitment of Tc1 cells capable of mediating
therapeutic efficacy; therefore, it is likely that the efficacy
Poly-ICLC administration induces IFN-α in serum of treated mice Figure 7
Poly-ICLC administration induces IFN-α in serum of treated mice. Peripheral blood samples were drawn from the 
tail vein at 0, 12, 24 and 48 hrs following i.m. poly-ICLC (50 µg) treatment. Serum IFN-α levels were determined using specific 
ELISA (Endogen, Rockford, IL). The average values of 3 mice in treated (■ ) or non-treated (▲ ) mice are depicted (n = 3/
group). Systemic induction of IFN-α in serum peaked at 24 hrs following the poly-ICLC injection, whereas control mice with 
no poly-ICLC administration did not display any elevation in IFN-α levels.
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of poly-ICLC assisted vaccines observed in our current
study also relies on IP-10. In addition to human astrocytes
[3], our preliminary data indicate U87 human glioma
cells also express functional TLR3 (unpublished observa-
tions), suggesting the clinical relevance of direct TLR3
stimulation on glioma cells. We are currently evaluating
whether i.m. administered poly-ICLC can directly stimu-
late GL261 tumors injected into the brain.
In contrast to GL261, M05 cells did not express detectable
levels of TLR3, nor could they directly respond to poly-
ICLC in vitro (data not shown), although they did express
high levels of IP-10 in response to IFN-γ treatment [1].
Based on the IFN-γ expression by BILs in i.c. M05 tumors
following poly-ICLC assisted vaccinations, it is possible
that BIL-derived IFN-γ production may have induced
M05-tumor expression of MHC class I molecules and
secretion of IP-10. Collectively, our data suggest that poly-
ICLC may promote the attraction of vaccine-induced CTLs
via direct and/or indirect induction of chemokines, such
as IP-10, and promote the target tumor-cell recognition by
the CTLs via upregulated MHC class I regardless of the
endogenous TLR3 status of the tumor cells.
With regard to a preferred vaccine formulation for the
treatment of gliomas, we believe that use of multiple pep-
tides has a clear advantage over strategies with a single
peptide. Given the marked antigenic heterogeneity of gli-
omas, immunotherapy with a single tumor-specific T-cell
epitope might merely promote transient stabilization of
disease, prior to the progression of antigen-loss variants
[48]. We therefore remain dedicated to broaden the list of
Poly-ICLC stimulates GL261 glioma-expression of IFN-beta, TLR3, MHC class I and IP-10 Figure 8
Poly-ICLC stimulates GL261 glioma-expression of IFN-beta, TLR3, MHC class I and IP-10. In vitro cultured GL261 
cells were treated with or without 50 µg/ml poly-ICLC for 24 hrs, and evaluated for expression of IFN-β in culture-superna-
tant by specific ELISA (A), surface TLR3 (B) and H-2Kb (C) by flow-cytometry, and for production of IP-10 in culture-superna-
tant by specific ELISA (D). (B), Dashed thin line: isotype control antibody, Thin line: TLR3 expression without poly-ICLC 
treatment, Bold line: TLR3 expression in the presence of poly-ICLC. (C), Black thin line: isotype control antibody, Dashed thin 
line: H-2Kb expression without poly-ICLC treatment, Filled grey area: H-2Kb expression with poly-ICLC treatment and control 
isotype-IgG, Black thick line: H-2Kb expression with poly-ICLC treatment and neutralizing anti IFN-β mAb.
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available human CTL-epitopes for integration into multi-
epitope-based vaccine strategies for glioma therapy
[23,27]. As the three GAAs we employed in the current
study represent self-Ags with no tumor-specific mutations,
they appear reflective of most defined human cancer Ags/
epitopes (reviewed in [49]). Therefore, we believe that our
GL261 tumor model that integrates therapies based on
these GAA-epitopes will continue to serve as a highly clin-
ically relevant model that limits concerns for inherited
immunogenicity and genetic drifts associated with chem-
ically-induced murine glioma models [50].
Our studies also indicate the lack of demyelination or
increased immune-cell infiltrate in the normal CNS using
LFB and H/E staining, which supports the absence of
severe CNS-autoimmunity as a collateral pathologic event
that might be associated with our combinational treat-
ment regimen. Given the caveat that these data reflect
those of short-term treatment, however, longer-term
assessments are clearly warranted and we recognize that
IHC will be invaluable in identifying the nature of infil-
trating immune cells.
Conclusion
Taken together, our current study demonstrated that poly-
ICLC assisted Ag-specific vaccines may represent an effi-
cient and safe therapeutic approach for CNS tumors.
Future studies will attempt to elucidate detailed mecha-
nisms underlying the enhanced induction of Type-1 Ag-
specific T-cell responses by this treatment strategy.
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